- $3.36m
- -$3.72m
- $0.07m
- 16
- 26
- 32
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 46.65 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.75% | ||
| Return on Equity | -78.37% | ||
| Operating Margin | -6526.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 12.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. It is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. Its lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 3rd, 2012
- Public Since
- January 5th, 2012
- No. of Shareholders
- 95
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 4,484,456
- Address
- 677 N. Washington Blvd, SARASOTA, 34236
- Web
- https://silopharma.com/
- Phone
- +1 7184009031
- Auditors
- Salberg & Company, P.A.
Upcoming Events for SILO
Q2 2025 Silo Pharma Inc Earnings Release
Similar to SILO
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
What is the Silo Pharma share price?
As of Today at 23:16 UTC, shares in Silo Pharma are trading at $0.75. This share price information is delayed by 15 minutes.
How has the Silo Pharma share price performed this year?
Shares in Silo Pharma last closed at $0.75 and the price had moved by -59.46% over the past 365 days. In terms of relative price strength the Silo Pharma share price has underperformed the S&P500 Index by -63.44% over the past year.
What are the analyst and broker recommendations for Silo Pharma?
The overall consensus recommendation for Silo Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Silo Pharma dividend yield?
Silo Pharma does not currently pay a dividend.
Does Silo Pharma pay a dividend?
Silo Pharma does not currently pay a dividend.
When does Silo Pharma next pay dividends?
Silo Pharma does not currently pay a dividend.
How do I buy Silo Pharma shares?
To buy shares in Silo Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Silo Pharma?
As of the previous close price of $0.75, shares in Silo Pharma had a market capitalisation of $3.36m.
Where are Silo Pharma shares listed?
Here are the trading details for Silo Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SILO
What kind of share is Silo Pharma?
Based on an overall assessment of its quality, value and momentum Silo Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Silo Pharma share price forecast for 2025?
The analyst consensus target price for shares in Silo Pharma is $10.00. That is 1233.33% above the last closing price of $0.75.
Analysts covering Silo Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$0.70 for the next financial year.
Find out moreWhat is the trend in the Silo Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Silo Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -28.24%.
As of the last closing price of $0.75, shares in Silo Pharma were trading -41.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Silo Pharma PE Ratio?
The Silo Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Silo Pharma?
Silo Pharma's management team is headed by:
- Eric Weisblum - CHM
- Wayne Linsley - DRC
- Kevin Munoz - IND